Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb Study of Intravenous HUCV002-01 in Chronic Heart Failure
jRCT2073220002Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Apr 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HUCV002-01 in chronic heart failure (CHF), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Change in left ventricular ejection fraction from baseline to 24 weeks. Started Apr 2022; status: active, not recruiting.
02
Drugs
HUCV002-01
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on jRCT2073220002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2073220002.